Antifungal Susceptibility Testing of C. auris

Antifungal susceptibility of all clinical isolates and the two control strains was determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.3.2 microdilution method [18 ]. Each isolate was tested against the following eight antifungals (values represent the final concentrations after inoculation): anidulafungin (ANI; 0.008–16 mg/L), micafungin (MCA; 0.008–16 mg/L), fluconazole (FLC; 0.125–256 mg/L), posaconazole (POS; 0.016–32 mg/L), voriconazole (VOR; 0.008–16 mg/L), 5-flucytosine (5-FC; 0.032–64 mg/L), amphotericin B (AMB; 0.032–16 mg/L), ibrexafungerp (IBX; 0.016–8 mg/L) provided by Scynexis (Jersey City, NJ, USA), and manogepix (MGP; 0.002–16 mg/L) provided by Pfizer (New York City, NY, USA). There are no established species-specific clinical breakpoints for C. auris in EUCAST guidelines [19 ].